Table SIII. Evidence table. First author (Ref), year Design Dosage Outcome measures Adalimumab Ryan (12), Date of evaluation
|
|
- Randolph Bell
- 5 years ago
- Views:
Transcription
1 Table SIII. Evidence table First author (Ref), year Design Dosage Outcome measures Adalimumab Ryan (12), 2009 (n = 39 a ) van Lümig (13), 2010 (n = 30 a ) Warren (14), 2010 (n = 46 a ) Retrosp b Adalimumab 80 mg (W 0) followed by 40 mg once W (from W1) SC or adalimumab 40 mg According to the response the dose interval was increased or decreased. Adalimumab 80 mg (W0) followed by 40 mg EOW (from W1 12) SC. From W12 48, according to the response the dose interval was maintained, increased or decreased. (Adalimumab 40 mg EOW or 40 mg every 10 days or 40 mg once W. Retrosp. Adalimumab 80 mg (W 0) followed by 40 mg increased to 40 mg weekly the first 4 months. Fotiadou (15), 2012 Retrosp. Adalimumab 80 mg (W 0) followed by 40 mg (n = 52 a ) According to the response the dose interval was increased or decreased López-Ferrer (16), 2013 (n = 119 a ) van Lümig (17), 2013 (n = 85 a ) Retrosp. Adalimumab 80 mg (W 0) followed by 40 mg EOW (From W1) SC. Adalimumab 80 mg (W 0) followed by 40 mg According to the response the dose interval was decreased. Monotherapy Date of evaluation Results (mean) W 16 : 38% : 62% : 69% W 72 : 71% combination therapy W 16 : 56% W24 : 50% W48 : 80% W72 : 67% 100 : 70% Comparing with original : 27% : 10% : 61% Comparing with original : 36% : 7% : 77% Comparing with original : 54% : 15% : 30% : 13% : 13% W 16 : 50% : 7% : 0% : 54% : 23% : 15% : 84% : 64% : 36% : 77% : 65% : 42% W 52 : 56% : 48% : 41% W 16 : 90% : 68% : 42% : 95% : 82% : 56% W 52 : 89% : 75% W 72 : 100% : 88% : 75% W 16 : 64% : 49% : 67% : 60% W 52 : 76% : 70% W 104 : 83% : 71% Comparing with original Comparing with original : 65% : 35% : 11% 100: 0% : 69% : 45% : 17% 100: 6%
2 Menting (18), 2014 (n = 90 TE a ) Adalimumab 80 mg (W 0) followed by 40 mg EOW (from W1) SC or 40 mg every 10 days or 40 mg once W. Etanercept de Groot (19), 2006 Retrosp. Etanercept 50 mg BIW SC (W0 12). (n = 50 a ) Berends (20), 2007 (n = 45 a ) Barrera (21), 2008 (n = 66) Etanercept 25 mg BIW SC (W0 12). by 25 mg BIW (W12 24). Naive Non-naive 25 mg BIW SC (W0 24). Retrosp. Etanercept 50 mg BIW SC (W0 12) followed by 25 mg BIW (W12 24) or 25 mg BIW (W0 24). Thereafter one of these treatments by losing 50% of the. Three cycles of 24W. : 83% Comparing with original : 57% : 21% 100: 4% W 96 : 94% Comparing with original : 44% : 22% 100: 0% W 132 : 83% Comparing with original : 50% : 0% 100: 0% : 46% : 27% : 8% W 96 W : 0% : 56% : 31% : 11% 100: 6% : 72% : 38% : 15% 100: 4% : 72% : 44% : 22% 100: 0% : 50% : 50% : 0% 100: 0% : 54% : 42.9% W 52 : 43.5% : 26% : 18% W 52 : 8% : 71% : 22.6% : 6.5% : 57.5% : 62.3% : 85.7% : 21.4% : 7.1% : 60% : 54.1% : 82% : 39% W 18 : 88% : 47% : 71% : 50% : 71% : 24% W 18 : 79% : 64% : 79% : 57% Cycle 1 Cycle 1 : 65.5% : 36.1% : 21.3% : 91.3% : 76.1% : 41.3% : 78.1%
3 Driessen (22), 2008 (n = 80 a ) by 25 mg BIW (W12 24). According to the response the dose of 25 mg BIW was temporary increased. Etanercept 25 mg BIW SC (W0 24). temporary increased. Cycle 2 : 72.4% : 31% : 10.3% Cycle 2 : 94.7% : 63.2% : 31.6% : 66.9%% Cycle 3 : 60% : 33.3% : 20% Cycle 3 : 85.7% : 42.9% : 28.6% : 76% : 66% : 20% : 8% : 59% : 68% : 21% : 5% : 60% Gisondi (40), 2008 Retrosp. Etanercept 25 mg BIW SC. : 74.5% (n = 58) Antoniou (23), 2009 (n = 77 a ) Retrosp. by 25 mg BIW (W12 48). : 79% : 53% increased to 50 mg BIW. : 81% : 49% Driessen (24), 2009 (n = 90 a ) Jiménez-Puya (25), 2009 (n = 58) Mazzotta (26), 2009 (n = 234) Warren (27), 2009 (n = 70 a ) by 25 mg BIW (W12 24) or Etanercept 25 mg BIW SC (W0 W24). temporary increased to 50 mg BIW. Retrosp. Etanercept 50 mg BIW SC or 25 mg BIW SC. c by 25 mg BIW (W12 24) Retrosp. Etanercept 25 mg BIW SC. increased to 50 mg BIW. (psoriasis) : 69% : 39% : 18% : 59.7% W 8 : 77.6% : 41.4% : 6.9% W 16 : 86.8% : 66% : 37.7% : 97.5% : 85% : 57.5% W 32 : 100% : 80.8% : 57.7% W 40 : 94.7% : 84.2% : 52.6% 48W : 100% : 92.3% : 69.2% : 85% : 77.9% : 41% : 67.7% : 85.7% : 73.2% : 81% : 64 % : 43% : 66.7% (psoriasis + psoriatic arthritis) : 79.8% : 61.8% : 80.5% : 67% : 35% : 7% : 55%
4 Antoniou (28), 2010 (n = 35 a ) van Lümig (13), 2010 (n = 30 a ) Zaragoza (29), 2010 (n = 43) Antoniou (30), 2011 (n = 118 a ) Esposito (31), 2012 (n = 61) van Lümig (32), 2012 (n = 152 a ) (n = 158 TE) Puig (33), 2012 (n = 444 a ) Retrosp. d by 25 mg BIW (W12 24). Etanercept 50 mg BIW SC or 25 mg BIW SC (W0 12). Thereafter dosage according to physician. Retrosp. c Etanercept 50 mg BIW SC (W0 12) or 25 mg BIW SC (W0 12) followed by 25 mg BIW SC (W12 24). increased or decreased. Retrosp. by 50 mg once W (from ). Retrosp. c Psoriasis patients with psoriatic arthritis: Etanercept 50 mg BIW SC. Patients with only psoriasis: Etanercept 50 mg BIW, followed by 25 mg BIW SC. Etanercept 50 mg BIW SC or 25 mg BIW SC (W0 12). Thereafter dosage according to the physician. Etanercept 50 mg BIW SC (W0 12) or 50 mg once W or 25 mg BIW (W0 12). After 12 W patients reaching a could continue treatment. After 6 months the decision was made to treat patients continuously or intermittently. : 67% : 41% : 6% : 59% : 57% MPhGAD : 60% : 13% : 3.3% : 58% : 19% : 3.3% : 79% : 25% : 81.4% : 60.5% : 73.8% : 90.5% : 71.4% : 79.6% W 72 : 81.3% W 96 : 38.2% 0 : 87.6% W 144 : 88.4% : 59% : 25% : 81% : 47% : 82% : 54% W 72 : 87% : 52% : 82% : 54.1% : 73.3% : 90.2% : 78.7% : 85.9% W 52 : 90.2% : 83.6% : 87.9% W 104 : 91.8% : 86.9% : 88.4% W 156 : 91.8% : 83.6% : 86.9% : 65.6% : 23.6% : 5.1% : 69.7% : 38.1% : 14.9% : 36.6% W 108 : 40.8% W 156 : 50% W 204 : 59.4% W 264 : 60% Overall Continuous regimen Intermittent regimen : 88.4% : 63.9% : 37.8% : 69.6% : 66.4% MPhGAD: 62.5% : 63% : 34.8% : 64% : 38.4%
5 Chiu (34), 2013 (n = 59 a ) van Lümig (35), 2013 (n = 131 a ) (n = 134 TE) Menting (18), 2014 (n = 178 TE a ) Infliximab Kalb (41), 2005 (n = 52 a ) Gisondi (40), 2008 (n = 40) Gisondi (36), 2013 (n = 83) Menting (18), 2014 (n = 40 TE a ) Retrosp. Etanercept 25 mg BIW SC (W0 24). increased to 50 mg BIW SC (for 4 12W). Thereafter dose was reduced to 25 mg BIW SC. Etanercept mean weakly dose 64.1 mg ± 14.0 mg. Etanercept initiated by 50 mg BIW SC (W0 12) or 50 mg once W or 25 mg BIW. Thereafter, 50 mg BIW or dose frequency reduction (every 5, 7 or 10 days). Naive Non-naive : 91.3% : 76.1% : 50.8% : 81.4% : 79.6% MPhGADR: 65.6% : 66.3% Continuous regimen : 39.3% : 79% Intermittent regimen : 54.3% W 36 : 73.9 : 52.6% : 32.1% : 63.4% : 66.7% MPhGAD: 46.9% W 36 : 68.8% Continuous regimen : 41.9% W 36 : 46.7% Intermittent regimen : 28.6% : 83.1% : 65.6% : 39.6% : 74.6% : 75.7% MPhGAD: 59.4% Continuous regimen Intermittent regimen : 69.2% : 47.3% PhGA 0 1: 73.4% : 64.3% : 36.6% PhGA 0 1: 61.8% : 48% : 26% : 3% : 47% : 59% : 37% : 14% : 61% : 67.9% : 38.1% : 14.9% : 36.6% W 108 : 40.8% W 156 : 50% W 204 : 59.4% W 264 : 60% : 32% : 9.9% W 52 : 13.3% : 12% : 4% W 52 : 13% Retrosp. Infliximab 5 mg/kg IV. PhGA 0 W 14 PhGA 0: 38.5% W 0, 2, 6 and every 8 W. PhGA 1 PhGA 1: 50% Retrosp. Infliximab 5 mg/kg W 0, 2, 6 and every 8 W. : 88.8% Infliximab 5 mg/kg W 0, 2, 6 and every 8 W. Infliximab ± 5 mg/kg W 0, 2, 6 and every 8 W. Naive W 4 : 32% PR: 64% W 28 : 96% : 69% : 85% : 53% : 35.3% W 52 : 18.2%
6 Ustekinumab Clemmensen (37), 2011 (n = 71) Laws (38), 2012 (n = 129 a ) Ruiz Salas (39), 2012 (n = 36 a ) Gisondi (36), 2013 (n = 79) Acitretin Piaserico (42), 2014 (n = 62) Fumarates Carboni (43), 2004 (n = 40) Inzinger (44), 2013 (n = 272) Non-naive : 38% : 12% W 52 : 14% W 16 : 80% Ustekinumab 45 or 90 mg (W 0, 4, and every 12 W). e Retrosp. Ustekinumab 45 or 90 mg (W 0, 4 and every W 16 : 82.7% 12 W. e : 63% : 29.1% : 66.7% : 65.5% Retrosp. Ustekinumab 45 mg (W 0, 4 and every 8 12 W). e Ustekinumab 90 mg (W 0, 4 and every 8 12 W). Ustekinumab both groups [45 and 90 mg] (W 0, 4 and every 8 12 W). Ustekinumab 45 or 90 mg (W 0, 4 and every 12 W). Dosing is weight dependent. Individuals weight ( 100 kg= ustekinumab 45mg; > 100kg= 90 mg). : 89.6% : 79.3% : 65.5% PR: 80.7% : 89.6% : 79.3% : 75.9% : 80.9% W 36 : 89.6% : 89.6% : 75.9% : 89.3% : 85.7% : 57.1% : 28.5% : 75.6% : 57.1% : 28.5% : 14.2% : 48.2% W 36 : 85.7% : 71.4% : 54.1% : 80% : 91.7% : 75% : 58.3% : 79.5% : 83.3% : 69.4% : 63.9% : 71.9% W 36 : 88.8% : 71.4% : 57.1% : 86.8% W 4 : 28% : 82% W 28 : 82% : 58% : 60% Retrosp. Acitretin mean 0.38 mg/kg/day. : 27% Fumarates mg/day. By remission doses were gradually reduced. Retrosp. Fumarates mg/day. W 4 : 39.6% : 63% : 80% 100 : 76% : 47% : 9% 100: 1% : 82% : 63% : 27% 100: 5%
7 : 90% : 76% : 34% 100: 12% Cyclosporine Piaserico 42), 2014 Retrosp. Cyclosporine mean 3.5 mg/kg/day. : 46% (n = 36) Methotrexate Gisondi (40), 2008 Retrosp. Methotrexate 15 mg/week IM. : 47.6% (n = 43) Inzinger (44), 2013 (n = 72) Piaserico (42), 2014 (n = 74) Retrosp. Methotrexate 10 mg/week SC increased to 20 mg/week SC. 100 W12 : 67% : 40% : 12% 100: 10% : 76% : 62% : 28% 100: 10% : 87.5% : 81% : 44% 100: 19% Retrosp. Methotrexate mean 11.7 mg/week. : 49% a Additional conventional systemic therapies. b Patient switched from etanercept. c Patients with psoriasis with or without psoriatic arthritis. d Patients switching from efalizumab. e Dosing is weight dependent. Individuals weight ( 100 kg= ustekinumab 45 mg; >100 kg= 90 mg). Retrosp.: retrospective; : prospective; BIW: biweekly; BSA: body surface area; : mean BSA decrease; EOW: every other week; IM: intramuscular; IV: intravenous; : Psoriasis Area and Severity Index; : mean decrease; PhGA: Physician Global Assessment; MPhGAD: mean PhGA decrease; SC: subcutaneous; TE: treatment episode.
This questionnaire was used both during the face-to-face interviews with the
Additional file 1: Primary research questionnaire This questionnaire was used both during the face-to-face interviews with the dermatologists and during the expert panel 1. During the last month, how many
More informationPsoriasis: Therapeutic goals
Psoriasis: Therapeutic goals I want to die 50 45 impetiginization infliximab 600 40 35 30 400 25 20 15 200 10 5 0 22-ene 21-feb 23-mar 22-abr 22- may Efalizumab 6 doses: flare + REBOUND CSA 3 21-jun 21-jul
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationClinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date:
Clinical Policy: (Orencia) Reference Number: ERX.SPA.123 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPA.01 Effective Date:
Clinical Policy: (Stelara) Reference Number: ERX.SPA.01 Effective Date: 04.01.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date:
Clinical Policy: (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationDrugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending
Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual
More information5 European S3-Guidelines on the Systemic Treatment of Psoriasis Vulgaris
87 5 European S3-Guidelines on the Systemic Treatment of Psoriasis Vulgaris Supported by the EDF/EADV/IPC Pathirana, D.; Ormerod, A. D.; Saiag, P.; Smith, C.; Spuls, P. I.; Nast, A.; Barker, J.; Bos, J.
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationchemotherapeutic agents in
Use of biologics and chemotherapeutic agents in cutaneous emergencies: Focus on lifethreatening forms of psoriasis Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationThe Treatment Toolbox for Severe Pediatric Psoriasis
The Treatment Toolbox for Severe Pediatric Psoriasis Dr. Kim A. Papp, MD, PhD, FRCPC, FAAD K Papp Clinical Research and Probity Medical Research Objectives: Treating severe pediatric psoriasis 1. Challenges
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationAccepted Article. Frequency of and predictors for a high clinical response in psoriasis patients on biologic therapy in daily practice
Received Date : 11-Apr-2016 Revised Date : 15-Jul-2016 Accepted Date : 15-Jul-2016 Article type : Original Article Frequency of and predictors for a high clinical response in psoriasis patients on biologic
More informationDrug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 5 Report June 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:
Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationAppendix 1: Frequently Asked Questions
Appendix 1: Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added to the Ontario Drug Benefit (ODB) Formulary
More informationOff-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy
: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy Elizabeth A. Brezinski 2, April W. Armstrong 1 * 1 Department of Dermatology, University of
More informationScottish Medicines Consortium
Scottish Medicines Consortium ustekinumab, 45mg solution for injection (Stelara ) No. (572/09) Janssen-Cilag Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationClinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Infliximab (Remicade), Infliximab-dyyb (Inflectra), and Infliximab-abda (Renflexis) Reference Number: ERX.SPA.160 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: ERX.SPA.122 Effective Date:
Clinical Policy: (Taltz) Reference Number: ERX.SPA.122 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationustekinumab (Stelara )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationDrug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 3 Report March 2012 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of the is to summarize
More informationClinical Policy: Anakinra (Kineret) Reference Number: ERX.SPA.135 Effective Date:
Clinical Policy: (Kineret) Reference Number: ERX.SPA.135 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1097-7 Program Prior Authorization/Notification Medication *Stelara (ustekinumab) *This program applies to the subcutaneous formulation
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationAnti-TNF biologic agents Dr Lluís Puig
Department of Dermatology Hospital de la Santa Creu i Sant Pau IPC NOVARTIS PSORIASIS PRECEPTORSHIP Anti-TNF biologic agents Dr Lluís Puig Barcelona, July 9th-10th, 2013 Anti-TNF therapy in the pathophysiology
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationTo help you with terms and abbreviations used in this document that may be unfamiliar to you, a glossary is provided on the last pages.
ARTHRITIS CONSUMER EXPERTS 910B RICHARDS STREET VANCOUVER BC V6B 3C1 CANADA T: 604.974-1366 F: 604.974-1377 WWW.ARTHRITISCONSUMEREXPERTS.ORG Arthritis Consumer Experts In Health Care and Research Decision-making
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationBJD British Journal of Dermatology. Summary. What s already known about this topic? GENERAL DERMATOLOGY
GENERAL DERMATOLOGY BJD British Journal of Dermatology Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective,
More informationJosephine Mauskopf Miny Samuel Doreen McBride Usha G. Mallya Steven R. Feldman
PharmacoEconomics (2014) 32:395 409 DOI 10.1007/s40273-014-0130-5 SYSTEMATIC REVIEW Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 05.18
Clinical Policy: (Taltz) Reference Number: CP.PHAR.257 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationSpecial Authorization Drug Products with
Effective August 1, 2008 Summary Special Authorization Drug Products with Changes to Criteria Special Authorization Drug Products with Changes to Criteria Alberta Blue Cross has been advised by Alberta
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Dimethyl fumarate for treating moderate to severe Draft scope (pre-referral) Draft remit/appraisal objective To appraise
More information1 x weekly 50 mg. Consumption:
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More information1.0 Abstract. Title. HUMIRA 40 mg syringe 0.8 ml for Subcutaneous Injection. Special investigation (All-case survey) in patients with Crohn's disease
1.0 Abstract Title HUMIRA 40 mg syringe 0.8 ml for Subcutaneous Injection Special investigation (All-case survey) in patients with Crohn's disease Keywords HUMIRA, adalimumab, All-case, PMOS, Crohn's Disease,
More informationBilaga 1.till rapport. Bilaga 1 Tabell över inkluderade studier/ Appendix 1 Description of included studies
Bilaga 1.till rapport Ljusbehandling och systemisk behandling av psoriasis, rapport nr 278 (2018) Bilaga 1 Tabell över inkluderade studier/ Appendix 1 Description of included studies Description of included
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationUSTEKINUMAB. London New Drugs Group APC/DTC Briefing Document. May 2009
Page 1 London New Drugs Group APC/DTC Briefing Document USTEKINUMAB Contents Summary 1 Background 4 Clinical efficacy 5 Cost implications 9 Reference list 10 Appendices 11 Produced for the London New Drugs
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:
Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationOntario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions
Ontario Public Drug Programs Inflectra (infliximab) Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added
More informationClinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date:
Clinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationTechnology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340
Ustekinumab for treating active psoriatic arthritis Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationThe implication of an immunologic
Evidence-Based Review of Biologic Therapy for Psoriasis: Infliximab, Etanercept, Adalimumab, Efalizumab, and Alefacept Jeffrey M. Weinberg, MD; Robin Buchholz, MD; Noah Scheinfeld, MD DERMATOLOGY ABSTRACT
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More informationClinical Policy: Ustekinumab (Stelara) Reference Number: CP.PHAR.264 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Stelara) Reference Number: CP.PHAR.264 Effective Date: 08.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 11.18
Clinical Policy: (Taltz) Reference Number: CP.PHAR.257 Effective Date: 08.01.16 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationAdrenocorticotropic hormone gel in patients with refractory rheumatoid arthritis: a case series
International Journal of Clinical Rheumatology For reprint orders, please contact: reprints@futuremedicine.com Adrenocorticotropic hormone gel in patients with refractory rheumatoid arthritis: a case series
More informationUpdate on systemic therapies and emerging treatments How do I choose a systemic agent?
Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University
More informationSTUDY. Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis
STUDY Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis Lidian L. A. Lecluse, MD; Rieke J. B. Driessen, MD; Phyllis I. Spuls, MD, PhD; Elke M.
More informationClinical Policy: Brodalumab (Siliq) Reference Number: CP.PHAR.375 Effective Date: Last Review Date: 05.18
Clinical Policy: (Siliq) Reference Number: CP.PHAR.375 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationustekinumab 130mg concentrate for solution for infusion and 90mg solution for injection (Stelara ) SMC No. (1250/17) Janssen-Cilag Ltd
ustekinumab 130mg concentrate for solution for infusion and 90mg solution for injection (Stelara ) SMC No. (1250/17) Janssen-Cilag Ltd 09 June 2017 The Scottish Medicines Consortium (SMC) has completed
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 13 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 May 2009 STELARA 45 mg, solution for injection B/1 x 0.5 ml vial (CIP code: 392 586-2) JANSSEN-CILAG Ustekinumab
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
DERBYSHIRE JOINT AREA PRERIBING COMMITTEE (JAPC) Derbyshire commissioning guidance on biologic drugs f the treatment of Rheumatoid arthritis with methotrexate This algithm is a tool to aid the implementation
More informationElements of Successful PBS Applications. Barbara Radulski RN. Copyright
Elements of Successful PBS Applications Barbara Radulski RN PBS Requirements April 1 2006 THE RULES PBS Requirements 18 years and over Psoriasis x 6 months Failed to achieve an adequate response to 3 systemic
More informationBreakthrough Drugs in Dermatology. Mark Lebwohl, MD
Breakthrough Drugs in Dermatology Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai LIFE CHANGING
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationLong-term ustekinumab treatment for refractory type I pityriasis rubra pilaris
DOI: http://dx.doi.org/10.331/jdcr.2013.1127 Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris Alessandro Di Stefani, Marco Galluzzo, Marina Talamonti, Andrea Chiricozzi, Antonio
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPA.167 Effective Date:
Clinical Policy: (Cimzia) Reference Number: ERX.SPA.167 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPA.167 Effective Date:
Clinical Policy: (Cimzia) Reference Number: ERX.SPA.167 Effective Date: 1.1.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationRequest for Special Authorization Enbrel
Certain prescription drugs call for a more detailed assessment to help ensure that they represent reasonable treatment. Special Authorization requires that you request approval from Great-West Life for
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationSTELARA (ustekinumab)
STELARA (ustekinumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationClinical Policy: Baricitinib (Olumiant) Reference Number: CP.PHAR.135 Effective Date: Last Review Date: 11.18
Clinical Policy: (Olumiant) Reference Number: CP.PHAR.135 Effective Date: 07.24.18 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationUvA-DARE (Digital Academic Repository) Innovative therapies and new targets in psoriasis de Groot, M. Link to publication
UvA-DARE (Digital Academic Repository) Innovative therapies and new targets in psoriasis de Groot, M. Link to publication Citation for published version (APA): de Groot, M. (2011). Innovative therapies
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:
Clinical Policy: (Tysabri) Reference Number: ERX.SPA.162 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationUstekinumab for the treatment of moderate to severe psoriasis
DOI: 10.3310/hta13suppl3/10 Health Technology Assessment 2009; Vol. 13: Suppl. 3 Ustekinumab for the treatment of moderate to severe psoriasis E Gospodarevskaya, J Picot, K Cooper, E Loveman* and A Takeda
More informationClinical Policy: Sarilumab (Kevzara) Reference Number: CP.PHAR.346 Effective Date: Last Review Date: 11.18
Clinical Policy: (Kevzara) Reference Number: CP.PHAR.346 Effective Date: 07.18.17 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationBJD. Summary. British Journal of Dermatology THERAPEUTICS
THERAPEUTICS BJD British Journal of Dermatology Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry
More informationErelzi (etanercept) Frequently Asked Questions
Erelzi (etanercept) Frequently Asked Questions 1. What is the funding status of Erelzi (etanercept)? Effective December 21, 2017, Erelzi (etanercept) will be added to the Ontario Drug Benefit (ODB) Formulary
More informationCombination Nonbiologic Therapy in Psoriasis. Sushil Tahiliani, MBBS, MD
Combination Nonbiologic Therapy in Psoriasis Sushil Tahiliani, MBBS, MD Agenda Rationale Preferred and less preferred combination Morphology-specific preferred combinations Doses used in combinations Potential
More informationInflectra Frequently Asked Questions
Inflectra Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Earlier in 2016, Inflectra (infliximab) was added to the Ontario Drug Benefit (ODB) Formulary as a Limited
More informationBritish Association of Dermatologists guidelines for biologic therapy for psoriasis 2017
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 IMPLEMENTATION TOOLKIT Table S1: SUMMARY OF LICENSED INDICATIONS AND POSOLOGY FOR BIOLOGIC THERAPY Table S2: DECISION
More informationClinical Policy: Anakinra (Kineret) Reference Number: CP.PHAR.244 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Kineret) Reference Number: CP.PHAR.244 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationPharmacy Management Drug Policy
SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: HIM.PA.SP17 Effective Date: 05.01.17 Last Review Date: 05.18 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder
More informationPsoriasiform Dermatitis in Children: Calling in the Troops
Psoriasiform Dermatitis in Children: Calling in the Troops Markus Boos, MD PhD Attending Physician, Dermatology Seattle Children s Hospital Assistant Professor of Pediatrics, University of Washington School
More informationCOST-EFFECTIVENESS OF TREATMENT FOR MODERATE-TO-SEVERE PSORIASIS
COST-EFFECTIVENESS OF TREATMENT FOR MODERATE-TO-SEVERE PSORIASIS Cheryl S. Hankin PhD 1 ; Steven R. Feldman, MD, PhD 2 ; Daniel Pearce, MD 2 1 BioMedEcon, San Jose, CA, USA; 2 Wake Forest University School
More informationPRODUCT INFORMATION HUMIRA
NAME OF THE MEDICINE Adalimumab (rch) DESCRIPTION PRODUCT INFORMATION HUMIRA (adalimumab) is a recombinant human immunoglobulin (IgG1) monoclonal antibody containing only human peptide sequences. was created
More informationUSTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE
Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA 36187 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of psoriatic arthritis (PsA)
More informationCADTH Therapeutic Review Panel
Therapeutic Review Panel Final Recommendations Biological Response Modifier Agents for Adults with Rheumatoid Arthritis July 2010 RECOMMENDATIONS The Therapeutic Review Panel (TRP) recommends that in adult
More informationSupplementary Online Content
Supplementary Online Content Lynch M, Higgins E, McCormick PA, et al. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis. JAMA
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationUstekinumab (Stelara )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION IXEKIZUMAB (Taltz Eli Lilly Canada Inc.) Indication: Moderate to Severe Plaque Psoriasis Recommendation: The CADTH Canadian Drug Expert Committee
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationActual use of medications is important for payers
ORIGINAL RESEARCH and Dosing for Plaque Psoriasis and Psoriatic Arthritis Machaon Bonafede, PhD, MPH; Derek H. Tang, PhD, BSPharm; Kathleen Wilson, MPH; Alice Huang, MS; David J. Harrison, PhD; and Bradley
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Examination of the dossier of medicinal products included on the reimbursement list for a period of 5
More informationPharmacy Medical Necessity Guidelines: Orencia (abatacept)
Pharmacy Medical Necessity Guidelines: Effective: October 23, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or
More information